CYTO.F Stock Overview
Operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Altamira Therapeutics Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.11 |
| 52 Week High | US$3.49 |
| 52 Week Low | US$0.07 |
| Beta | 2.54 |
| 1 Month Change | -0.45% |
| 3 Month Change | -78.00% |
| 1 Year Change | -93.82% |
| 3 Year Change | -99.98% |
| 5 Year Change | -99.98% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Altamira Therapeutics completes enrollment in trial of its nasal spray to treat COVID
Sep 13Altamira Therapeutics moving forward on plans to divest legacy assets, including Bentrio
Aug 30Altamira starts development program for potential arthritis therapy
Jul 25Altamira announces peer-reviewed publication on mRNA delivery platform
Jul 19Altamira gains on peer-reviewed preclinical data publication for its RNA delivery platform
Jul 12Auris Medical shares rise on OligoPhore Lymphoma study results
Jun 21Auris Medical starts preparations for COVID-19 trial with Bentrio in India
Jun 01Auris Medical updates on pollen challenge study for nasal spray
May 10Are Insiders Buying Auris Medical Holding Ltd. (NASDAQ:EARS) Stock?
Dec 09
Auris Medical prices $8M direct equity offering, stock -22%
Dec 02Shareholder Returns
| CYTO.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -10.6% | 4.2% | -0.5% |
| 1Y | -93.8% | 5.1% | 24.3% |
Return vs Industry: CYTO.F underperformed the US Pharmaceuticals industry which returned 5.1% over the past year.
Return vs Market: CYTO.F underperformed the US Market which returned 24.3% over the past year.
Price Volatility
| CYTO.F volatility | |
|---|---|
| CYTO.F Average Weekly Movement | 41.2% |
| Pharmaceuticals Industry Average Movement | 10.6% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 18.8% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: CYTO.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CYTO.F's weekly volatility has increased from 23% to 41% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 10 | Thomas Meyer | altamiratherapeutics.com |
Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens.
Altamira Therapeutics Ltd. Fundamentals Summary
| CYTO.F fundamental statistics | |
|---|---|
| Market cap | US$374.51k |
| Earnings (TTM) | -US$7.91m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs CYTO.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CYTO.F income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$7.91m |
| Earnings | -US$7.91m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.32 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CYTO.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/31 01:25 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Altamira Therapeutics Ltd. is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hunter Diamond | Diamond Equity Research LLC |
| Maxim Jacobs | Edison Investment Research |
| Christopher Howerton | Jefferies LLC |